hapabapa
Johnson & Johnson (NYSE:JNJ) has decided to resume a limited market rollout of its heart rhythm device Varipulse after an investigation indicated no safety concerns, the MedTech giant announced.
Shares of the New Brunswick, New Jersey-based healthcare giant came under pressure